The Natural & Non-Prescription Health Products Directorate (NNHPD) of Health Canada has reviewed and approved the claim “NEM helps provide relief from joint pain due to moderate intensity aerobic exercise as quickly as the first day.”
“The allowance of a pain claim after just one day of using NEM is a testament to the strength of science Stratum and ESM Technologies have put behind NEM. This approval is the culmination of more than 5 years of carefully designed research,” said Dr. Kevin J. Ruff, Senior Director of Scientific & Regulatory Affairs at Stratum, in the press release.
NEM is supported by 16 research studies, including four randomized placebo-controlled trials, four open label clinical trials, veterinary trials, and mechanism of action studies.
Related: Joint Health Ingredient Granted Pre-Market Approval in Brazil KSM-66 Ashwagandha Granted New Functional Claims by Health Canada Stratum, KD Pharma Partner on Clinically Backed Joint Health IngredientChris Haynes, Senior Director of Global Sales, said in the press release: “Canada’s scientific review process and subsequent strong claim allowances are a bellwether notification to anyone looking for an ingredient in the exercise/athletic supplement arena. NEM’s ability to help with workout recovery, post-workout pain related issues and cartilage preservation and even everyday aspects of joint related health is par excellence. NEM was initially developed for joint related support and has gone far beyond its goal to become the obvious choice for formulations dealing with periodic aches & pains, stiffness, inflexibility, and now sports/exercise formulations, too. The claims allowed by NNHPD are perfect for communicating to the consumer the benefits of NEM.”